Treace Medical Concepts (TMCI)
(Delayed Data from NSDQ)
$8.44 USD
-0.01 (-0.12%)
Updated Jul 17, 2024 04:00 PM ET
After-Market: $8.42 -0.02 (-0.24%) 7:58 PM ET
4-Sell of 5 4
D Value D Growth B Momentum D VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
TMCI 8.44 -0.01(-0.12%)
Will TMCI be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for TMCI based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for TMCI
Treace Medical Concepts (TMCI) Reports Q1 Loss, Tops Revenue Estimates
LivaNova (LIVN) Q1 Earnings and Revenues Top Estimates
TMCI: What are Zacks experts saying now?
Zacks Private Portfolio Services
Treace Medical Concepts (TMCI) Reports Q4 Loss, Tops Revenue Estimates
Glaukos (GKOS) Reports Q4 Loss, Tops Revenue Estimates
Globus Medical (GMED) Q4 Earnings and Revenues Beat Estimates
Other News for TMCI
TMCI Crosses Above Average Analyst Target
Treace Medical price target raised by $2 at Truist, here's why
Treace Medical Concepts: Facing Increasing Competitive Pressure
Analysts Offer Insights on Healthcare Companies: Arcus Biosciences (RCUS), Treace Medical Concepts (TMCI) and Veeva Systems (VEEV)
Treace Medical director buys $253.5K in common stock